For The Better

Is the social media company’s massive drop warranted?

The results weren’t nearly as bad as last week’s sell-off made them out to be.

Want more money from Social Security? Here’s how to pull it off.

These companies could upend the industry in the years ahead.

The coffee titan is back to setting sales records.

Could this legacy automaker pivot into the next generation of transportation?

Investors should look beyond the company’s COVID-19 vaccine.

The big bank posted a rare earnings disappointment for the second quarter.

Plus your investment would be worth nearly three times its original value.

Meme stocks have had an incredible year, but there are some important lessons all investors can learn from them.

One of our top banking experts talks about where he puts his own money.

The complex deal to acquire a stake in Universal Music fell through, but should investors sell or hold?

Relax — this surprising announcement is not the end of Micron’s growth ambitions.

The FDA recently approved Ultomiris as a treatment for paroxysmal nocturnal hemoglobinuria patients who are under 18, and it should get a similar label expansion in the E.U. soon.

ETFs can make you a millionaire, but you have to follow some investment rules to get there.

The grass is certainly not greener with this cannabis trio.

Retiring in one of these states could save you a ton of money.

Here’s how one Fool intends to fund her senior years.

IGT earnings call for the period ending June 30, 2021.

AVNS earnings call for the period ending June 30, 2021.